Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME) is a biotechnology company specializing in the development of next-generation multifunctional antibodies for the treatment of cancer and other diseases. Founded in 2008 and headquartered in Vancouver, Canada, Zymeworks utilizes proprietary platform technologies to engineer novel therapeutic candidates, aiming to improve efficacy and safety profiles for targeted therapies.
Company News
Zymeworks has decided to voluntarily discontinue clinical development of ZW171, a T cell engager targeting gynecological, thoracic, and digestive system cancers, after dose escalation phase revealed dose-limiting toxicities.
The oncology industry has seen significant progress, with cancer deaths falling by 33% in the last 30 years. Several key players, including Oncolytics Biotech, Novartis, Lantheus Holdings, Sutro Biopharma, and Zymeworks, have reported promising developments in their cancer research and treatments.
Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks has a strong financial position, with a robust liquidity position and a cash runway that extends into 2027. Learn why ZYME stock is a Buy.
These biotech companies are seeing a spike in revenue growth.